Skip to main content

Table 5 Effects of each treatment on TXB2, 6-keto-PGF and the TXB2/6-keto-PGF1a ratio in k-carrageenan-induced rat tail thrombosis model (n = 10)

From: Evaluation on antithrombotic effect of aspirin eugenol ester from the view of platelet aggregation, hemorheology, TXB2/6-keto-PGF and blood biochemistry in rat model

Groups TXB2 6-keto-PGF TXB2/6-keto-PGF
Control 498 ± 32## 889 ± 28## 0.56 ± 0.04##
Model 696 ± 39 586 ± 24 1.19 ± 0.08
CMC-Na 703 ± 37 550 ± 22## 1.28 ± 0.08##
Aspirin 658 ± 44* 741 ± 23** 0.89 ± 0.06**
Eugenol 678 ± 58 699 ± 30** 0.97 ± 0.09**
AEE L 605 ± 22** 667 ± 17** 0.91 ± 0.04**
AEE M 612 ± 45** 737 ± 13** 0.83 ± 0.07**
AEE H 644 ± 23** 599 ± 26** 1.08 ± 0.07**
Combination 598 ± 51** 701 ± 31** 0.86 ± 0.10**
  1. Blood samples anticoagulated with EDTA-K2 were centrifuged at 1000 g for 10 min to obtain plasma, which was analyzed using ELISA kits. Data are expressed as mean ± SD. ## P < 0.01 compared with the model group. *P < 0.05, **P < 0.01 compared with the CMC-Na group. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)